DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "EpiCast Report: Immune Thrombocytopenia (ITP) - Epidemiology Forecast to 2025" drug pipelines to their offering.
Epidemiologists selected nationally representative population-based studies, peer-reviewed journals, and registries (for example: GPRD, JIDIC) that used Read codes which are cross-referenced with ICD-9 and ICD-10 (D69.3) codes to diagnose ITP. ITP was defined as having platelet levels between 100-150 x 109/L.
In the 7MM, the diagnosed prevalent cases of primary and secondary ITP will increase from 359,208 cases in 2015 to 384,780 cases in 2025 at an annual growth rate (AGR) of 0.71%. The 5EU will have the highest number of diagnosed prevalent cases throughout the forecast period with 179,350 cases in 2015 and 191,229 cases in 2025, while Japan will have the lowest number of diagnosed prevalent cases with 24,468 in 2015 and 24,479 in 2025.
In the 7MM, the diagnosed incident cases of primary and secondary ITP will increase from 33,136 cases in 2015 to 35,364 cases in 2025, at an AGR of 0.67%.
- The Immune Thrombocytopenia (ITP) EpiCast Report provides an overview of the risk factors and global trends of NSCLC in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent and diagnosed incident cases of ITP segmented by type (primary and secondary), sex, and age.
- The ITP epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
The EpiCast Report is in-depth, high quality, transparent and
market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy
- Develop business strategies by understanding the trends shaping and driving the global ITP market.
- Quantify patient populations in the global ITP market to improve product design, pricing, and launch plans.
Key Topics Covered:
1 Tables & Figures
2.1 Disease Background
2.2 Risk Factors and Comorbidities
2.3 Global Trends
2.4 Forecast Methodology
2.4.1 Sources Used Tables
2.4.2 Forecast Assumptions and Methods
2.4.3 Sources Not Used
2.5 Epidemiological Forecast for ITP (2015-2025)
2.5.1 Diagnosed Prevalent Cases of ITP
2.5.2 Age-Specific Diagnosed Prevalent Cases of ITP
2.5.3 Sex-Specific Diagnosed Prevalent Cases of ITP
2.5.4 Age-Standardized Diagnosed Prevalence of ITP
2.5.5 Diagnosed Incident Cases of ITP
2.5.6 Age-Specific Diagnosed Incident Cases of ITP
2.5.7 Sex-Specific Diagnosed Incident Cases of ITP
2.5.8 Age-Standardized Diagnosed Incidence of ITP
2.6.1 Epidemiological Forecast Insight
2.6.2 Limitations of the Analysis
2.6.3 Strengths of the Analysis
For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/lp7q57/epicast_report